Condition: Neuroendocrine Carcinomas (NEC) · Neuroendocrine Carcinoma of Pancreas · Neuroendocrine Carcinoma of Prostate · Sponsor: Inkeun Park
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), followed by administration every two weeks thereafter. No placebo control is included in this study.
This description comes directly from the study's public registry record.
Inkeun Park, M.D, Ph D · +82-2-3010-3266 · ikpark@amc.seoul.kr
Hung-Don Kim, M.D, Ph D · +82-2-3010-0236 · kimhdmd@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Not Yet Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Yonsei Severance Hospital | Seoul, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06893783